<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04907747</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0446</org_study_id>
    <nct_id>NCT04907747</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Vonoprazan as First-line Treatment for Helicobacter Pylori Eradication</brief_title>
  <official_title>Efficacy and Safety of Furazolidone-based Quadruple Therapy With Vonoprazan as First-line Treatment for Helicobacter Pylori Eradication: A Prospective Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the efficacy of vonoprazan compared with esomeprazole as&#xD;
      first-line treatment for Helicobacter Pylori(Hp) eradication, as well as the safety and&#xD;
      economic benefits.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vonoprazan, a novel potassium-competitive acid blocker, is proved to be superior to proton&#xD;
      pump inhibitor in gastric acid-related diseases such as reflux esophagitis, as the increase&#xD;
      of intragastric pH maintains for a longer period. Vonoprazan, therefore, is a promising&#xD;
      candidate in helicobacter pylori eradication as the antibiotic resistance is rising.&#xD;
&#xD;
      This study will enroll 234 patients, and randomly assigned by computer to one of the three&#xD;
      treatment groups.&#xD;
&#xD;
      Group A: Vonoprazan taken with bismuth, amoxicillin, furazolidone for 10 days Group B:&#xD;
      Vonoprazan taken with bismuth, amoxicillin, furazolidone for 14 days Group C: Esomeprazole&#xD;
      taken with bismuth, amoxicillin, furazolidone for 14 days Participants will visit the clinic&#xD;
      for a follow-up assessment 6-8 weeks after the course of treatments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 18, 2021</start_date>
  <completion_date type="Anticipated">April 13, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 13, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Helicobacter pylori Eradication Rate</measure>
    <time_frame>Six to eight weeks after completion of the medication</time_frame>
    <description>Helicobacter pylori Eradication will be determined by ¹³C-urea breath test six to eight weeks after completion of the medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Adverse Drug Reaction(ADR)</measure>
    <time_frame>Within 7 days after completion of therapy</time_frame>
    <description>Adverse drug reactions are classified into six types (with mnemonics): dose-related (Augmented), non-dose-related (Bizarre), dose-related and time-related (Chronic), time-related (Delayed), withdrawal (End of use), and failure of therapy (Failure).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance Rate</measure>
    <time_frame>Within 7 days after completion of therapy</time_frame>
    <description>Compliance was defined as poor when they had taken less than 80% of the total medication.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">234</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Group A: Vonoprazan taken with bismuth, amoxicillin, furazolidone for 10 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vonoprazan 20mg qd, Colloidal bismuth pectin 200mg bid, Amoxicillin 1.0g bid, Furazolidone 0.1g bid for 10days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Vonoprazan taken with bismuth, amoxicillin, furazolidone for 14 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vonoprazan 20mg qd, Colloidal bismuth pectin 200mg bid, Amoxicillin 1.0g bid, Furazolidone 0.1g bid for 14days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C: Esomeprazole taken with bismuth, amoxicillin, furazolidone for 14 days</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Esomeprazole 20 mg bid, Colloidal bismuth pectin 200mg bid, Amoxicillin 1.0g bid, Furazolidone 0.1g bid for 14days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vonoprazan</intervention_name>
    <description>Potassium-competitive acid blocker</description>
    <arm_group_label>Group A: Vonoprazan taken with bismuth, amoxicillin, furazolidone for 10 days</arm_group_label>
    <arm_group_label>Group B: Vonoprazan taken with bismuth, amoxicillin, furazolidone for 14 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>Proton pump inhibitor</description>
    <arm_group_label>Group C: Esomeprazole taken with bismuth, amoxicillin, furazolidone for 14 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colloidal bismuth pectin</intervention_name>
    <description>Gastric mucosal protective drug with anti-H. pylori effect</description>
    <arm_group_label>Group A: Vonoprazan taken with bismuth, amoxicillin, furazolidone for 10 days</arm_group_label>
    <arm_group_label>Group B: Vonoprazan taken with bismuth, amoxicillin, furazolidone for 14 days</arm_group_label>
    <arm_group_label>Group C: Esomeprazole taken with bismuth, amoxicillin, furazolidone for 14 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>Antibiotic for H. pylori eradication</description>
    <arm_group_label>Group A: Vonoprazan taken with bismuth, amoxicillin, furazolidone for 10 days</arm_group_label>
    <arm_group_label>Group B: Vonoprazan taken with bismuth, amoxicillin, furazolidone for 14 days</arm_group_label>
    <arm_group_label>Group C: Esomeprazole taken with bismuth, amoxicillin, furazolidone for 14 days</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furazolidone</intervention_name>
    <description>Antibiotic for H. pylori eradication</description>
    <arm_group_label>Group A: Vonoprazan taken with bismuth, amoxicillin, furazolidone for 10 days</arm_group_label>
    <arm_group_label>Group B: Vonoprazan taken with bismuth, amoxicillin, furazolidone for 14 days</arm_group_label>
    <arm_group_label>Group C: Esomeprazole taken with bismuth, amoxicillin, furazolidone for 14 days</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Helicobacter pylori-positive participants determined by ¹³C-urea breath test, ¹⁴C-urea&#xD;
             breath test, HE stain or bacterium culture&#xD;
&#xD;
          2. With no historical treatment for helicobacter pylori infection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Administration of antibiotics, bismuth in 4 weeks prior to inclusion or antacids&#xD;
             including H2 receptor antagonist, proton pump inhibitor and potassium-competitive acid&#xD;
             blocker in 2 weeks prior to inclusion&#xD;
&#xD;
          2. Active peptic ulcer with complications such as hemorrhage, perforation, obstruction,&#xD;
             cancerization, etc.&#xD;
&#xD;
          3. With previous esophageal or gastric surgery&#xD;
&#xD;
          4. With severe systemic diseases, major organ like heart, lung, brain diseases, liver or&#xD;
             kidney insufficiency, malignant tumor or other diseases&#xD;
&#xD;
          5. Allergy to any of the study drugs&#xD;
&#xD;
          6. Pregnancy or in lactation&#xD;
&#xD;
          7. Participated in other research within 3 months，cannot express his/her own ideas&#xD;
             correctly or cannot cooperate with the researcher&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qin Du, Master</last_name>
    <phone>+86 0571-89713734</phone>
    <email>duq518@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Zhejiang University, School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qin Du, Master</last_name>
      <phone>+86 0571-89713734</phone>
      <email>duq518@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 24, 2021</study_first_submitted>
  <study_first_submitted_qc>May 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2021</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Helicobacter pylori</keyword>
  <keyword>vonoprazan</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Furazolidone</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

